Date:10/30/2008

overnment regulation affecting our diagnostic products could harm our sales and increase our development costs, (xi) the risk that our intellectual property may be infringed by third parties or invalidated, and (xii) our involvement in patent and other intellectual property and commercial litigation could be expensive, could divert management's attention, and could interfere with our ability to develop and distribute products. The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Sr. director, investor relations and

corporate communications

858-410-8673

Gen-Probe Incorporated

Consolidated Balance Sheets

(In thousands, except share and per share data)

September December

30, 31,

2008 2007

(Unaudited)

Assets

Current assets:

Cash and cash equivalents $74,366 $75,963

Short-term investments 481,127 357,531

Trade accounts receivable, net of allowance

for doubtful accounts of $700 and $719 at

Septemb
'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
4. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
5. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
6. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
8. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
9. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Nuvelo Reports Third Quarter 2008 Financial Results